Trial Profile
A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Sinapultide (Primary)
- Indications Neonatal respiratory distress syndrome
- Focus Adverse reactions
- Sponsors Windtree Therapeutics
- 09 May 2019 According to a Windtree Therapeutics media release, new post-hoc, pooled analysis of two randomized, controlled phase 2 studies (NCT02528318 and NCT02636868) of premature infants with respiratory distress syndrome, were presented at the Pediatric Academic Societies (PAS) Meeting (2019).
- 09 May 2019 Results of new post-hoc, pooled analysis of two randomized, controlled phase 2 studies (NCT02528318 and NCT02636868) of premature infants with respiratory distress syndrome, presented in a Windtree Therapeutics media release.
- 28 Dec 2017 According to a Windtree Therapeutics media release, updated results of this trial will be discussed in conference call and live webcast on January 4, 2018.